Cogent Biosciences (COGT) Current Leases (2019 - 2026)

Cogent Biosciences (COGT) has 8 years of Current Leases data on file, last reported at $1.4 million in Q1 2026.

• On a quarterly basis, Current Leases fell 14.15% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $1.4 million, a 14.15% decrease from a year earlier, with the FY2025 full-year figure at $1.5 million, down 1.15% from the prior year.
• Current Leases for Q1 2026 stood at $1.4 million, down from $1.5 million in the prior quarter.
• Over the last five years, Current Leases for COGT reached as high as $9.1 million in Q2 2022 and fell as low as $947000.0 in Q1 2023.
• Historically, Current Leases has averaged $2.0 million across 5 years, with a median of $1.5 million in 2024.
• Across the five-year window, Current Leases soared 314.7% in 2022 and sank 87.0% in 2023, its largest moves.
• Year by year, Current Leases stood at $1.4 million in 2022, then dropped by 2.6% to $1.4 million in 2023, then gained by 12.91% to $1.6 million in 2024, then slipped by 1.15% to $1.5 million in 2025, then retreated by 10.6% to $1.4 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $1.4 million in Q1 2026, $1.5 million in Q4 2025, and $1.7 million in Q3 2025.